1. CREATING POSTERS that STAND OUT!
Beth S. Gottlieb, MD, MS
Division of Pediatric Rheumatology
Cohen Children’s Medical Center of New York
North Shore-Long Island Jewish Health System

2. Plan, Plan, Plan! Know your requirements! Know the size of the poster
Know the directionality
Usually horizontal
Easel? Tacks?
Invest in a poster carrying case or ship to the hotel (back-up copy!)

3. Plan, Plan, Plan! How much time will printing take?
Allow time for someone else to review it
How much does it cost?
Who’s paying?

4. Plan, Plan, Plan! Companies that help
Provide free templates
Pricing guide
Free templates and tutorial
North Shore - LIJ Xerox Print center

5. Plan, Plan, Plan! Keep it simple Institution name and logo
Co-Author names
How do they want their names to appear?
Abstract and references on a handout

6. Poster Lay-out
Title
Title

7. Poster Lay-out Title Logo Institution Introduction Conclusions Methods
Limitations
Results

8. Steven and Alexandra Cohen Children’s Medical Center of New York
Title
Authors
Steven and Alexandra Cohen Children’s Medical Center of New York
Background
Findings
Conclusion
Insert Text
Insert Text
Next Steps
Insert Text
Problem Statement
Insert Text
Results
Acknowledgements
Insert Text
Insert Text
Evidence
Insert Text
References
Insert Text

9. Plan, Plan, Plan! Font – easy to read – sans serif Verdana, Arial
Use colors to direct attention
Readers start at top left and bottom right
Avoid more than 2 fonts

10. Images Photos and Images need 1200x1000 Resolution Crop Google Images
Often can’t enlarge
Copyright! Be careful

11. Working with Images
Good to Crop
Bad to Enlarge

12. General Rules: Don’t list raw data Use tables Avoid too much text
40% graphic
20% text
40% blank space

13. Final Version? Title Be able to read it from 20 feet away Body
Can you read it from 6 feet away?

14. Final Version? Final copy Is it pleasant to look at?
Would you stop to read it?

16. Stools from asymptomatic pediatric inpatients at risk for Clostridium difficile-associated diarrhea frequently test positive for C. difficile using a commercial PCR assay.
Jill Leibowitz MD, Vijaya L Soma MD, Lorry G Rubin MD
Division of Infectious Diseases
Steven and Alexandra Cohen Children’s Medical Center of New York
Background
Results
Conclusion
Clostridium difficile is an important cause of nosocomial diarrhea in adults and possibly in children.
There is a high rate of asymptomatic C. difficile carriage in children < 2 years of age.
Data on rates of carriage in older children is limited.
Many laboratories including CCMC now use highly sensitive polymerase chain reaction (PCR)-based stool assays to detect C. difficile toxin DNA.
However, a positive PCR result indicates only the presence of toxin-encoding DNA, not necessarily toxin production and disease.
Therefore, there is the potential for false positive results.
We sought to determine the background detection rate of C. difficile by PCR in pediatric patients without diarrhea but at high risk for developing CDAD.
C. difficile PCR assays are frequently positive in hospitalized children both with and without diarrhea.
Stools positive by PCR are frequently negative by cytotoxicity testing.
Given our results, it is unclear what proportion of positive PCR tests in symptomatic patients are true-positive results (versus false-positive) given the absence of a gold standard for the diagnosis of C. difficile disease.
Our findings suggest that a positive C. difficile PCR test result in a hospitalized child with diarrhea should be interpreted with caution.
Acknowledgements
The authors acknowledge the contribution of the personnel of the LIJ microbiology laboratory.
Methods
References
Informed consent was obtained & stool was collected from inpatients 1-18 years of age without diarrhea.
Stools were tested for C. difficile toxin DNA using a commercial C. difficile toxin PCR assay (Xpert C. difficile/Epi, Cepheid, Sunnydale, CA).
Results of PCR tests of stools from inpatients 1-18 years with diarrhea who had specimens submitted to the clinical laboratory were also tabulated.
A cytotoxicity assay (Cytotoxicity Assay for Clostridium difficile Toxin, Bartels, Carlsbad, CA) was performed as per the manufacturer’s instructions on PCR-positive specimens.
Demographic, clinical, and laboratory data for both groups were abstracted.
Proportions were compared using Fisher’s Exact Test and medians were compared using Mann-Whitney test.
Asymptomatic Inpatients
Clinical Features
PCR +
PCR -
P value
Median age
7 y
6.5 y
p=0.71
Median Hosp days 5 4
p=0.6
Abx prior 30 days
77%
78%
p=1.0
Median days Abx during past 30 days 3
p=0.87
Hosp. prior 60 days
31%
28%
Ellis ME, Mandal BK, Dunbar EM. Clostridium difficile and its cytotoxin in infants admitted to the hospital with infectious gastroenteritis. Br Med J. 1984; 288:
Oguz F, Uysal G, Dasdemir S. The role of Clostridium difficile in childhood nosocomial diarrhea. Scand J Infect Dis. 2011; 33:
Burgner D, Siarakas S, Eagles G et al. A prospective study of Clostridium difficile infection and colonization in pediatric oncology patients. Pediatr Infect Dis J. 1997; 16:
Sandora TJ, Fung M, Flaherty K et al. Epidemiology and risk factors for Clostridium difficile infection in children. Pediatr Infect Dis J. 2011; 30:
Luna RA, Boyanton BL, Mehta S. Rapid stool- based diagnosis of Clostridium difficile infection by real- time PCR in a children’s hospital. J Clin Microbiol. 2011; 49:

17. Thyroid binding globulin
KWASHIORKOR IN A STUBBORN TODDLER Samuel Bitton, Toba Weinstein, Jeremiah Levine, Michael Pettei Cohen Children’s Medical Center, North Shore-Long Island Jewish Health System, New Hyde Park, New York
BEFORE
48 HOURS AFTER
Erythematous, desquamating rash that involved most of the patient’s body and pedal edema, both markedly improved after 48 hrs of NG tube feeds
Treatment
-Treatment involves feeding an appropriate protein sufficient diet with attention to any other associated nutritional deficiencies
In our case, we treated with a standard, nutritionally-complete formula via NG tube to overcome behavioral feeding problems
Must monitor for development of refeeding syndrome manifested by:
Hypophosphatemia
Hypokalemia
Hypomagnesemia
Pancreatitis
Discussion
Kwashiorkor in North America has been reported in infants on inappropriate low protein (often hypoallergenic) diets
The differential diagnosis of dermatitis and edema includes:
-Atopic dermatitis, viral exanthema, staphylococcal scalded skin syndrome, zinc deficiency, scabies, tinia corporis, Langerhans cell histiocytosis, epidermolysis bullosa
The diagnosis of kwashiorkor was delayed in our case --- even with a bizarre dietary history, consultation with a dermatologist and presentation with the typical features of kwashiorkor --- likely due to its low prevalence in the United States
Conclusion
When a child presents with skin manifestations and a clearly inappropriate diet, careful consideration must be given to conditions caused by nutritional deficiencies, including locally rare but well-characterized nutritional diseases
Background
Kwashiorkor – Definition: severe protein-calorie malnutrition characterized by relatively greater deficiency of protein over calories
Characteristic clinical features: edema, dermatoses (‘flaky-paint’ dermatosis), abdominal distension, and hepatomegaly
Common in developing regions of the world such as South Asia and Sub-Saharan Africa due to food insufficiency
Rare in the US without a predisposing condition.
Kwashiorkor has been reported in US infants placed on inappropriate diets, e.g., rice or almond milk based diets
Case History
3.5 year old boy from suburban Long Island, NY
Presented with a worsening, 2-month-long rash and recent development of pedal edema with difficulty walking
Behavioral feeding issues, characterized by a progressively limited dietary intake, began at about 12 months of age after several viral illnesses
Ultimately, his diet consisted of only orange juice and a commercial banana purée preparation over the last 4 to 6 months prior to presentation
Clinical features:
BMI <3%
irritability
rounded facies
protuberant abdomen without hepatomegaly
a diffuse, erythematous, pruritic, ‘flaking-paint’ rash
pedal edema
Significant Lab Values
TEST
RESULT
NORMAL RANGE
Albumin
2.6 g/dL
3.3 – 5 g/dL
Transferrin
70 mg/dL
200 – 360 mg/dL
Thyroid binding globulin
11 μg/ml
12 – 26 μg/ml
Prealbumin
10 mg/dL
20 – 40 mg/dL
Linoleic acid
1232 μmol/L
1600 – 3500 μmol/L
Zinc
0.55 μg/ml
μg/ml
Copper
0.47 μg/ml
μg/ml

18. #732
Early Administration of Intravenous Terbutaline in Severe Pediatric Asthma
May Reduce the Incidence of Acute Respiratory Failure
Sule Doymaz1, M.D., James Schneider1, M. D., Mayer Sagy2, M. D.
The Divisions of Pediatric Critical Care Medicine at 1Cohen Children’s Medical Center of New York, New Hyde Park, NY and 2New York University Medical Center, New York, NY.
Please place NHS/LIJ
logo/emblem here
Contact Information:
Results
Of the 120 patients studied, 118 survived and 2 died (brain death) in the PICU from an earlier episode of cardiac arrest at home.
Thirty-five (35) patients were transferred from outlying ED(s) and 85 patients from our ED; these two categories of patients were clinically and demographically similar (figure 1).
In 25 patients (71%) from outlying EDs, and in only 17 pts (20%) from our own ED terbutaline started after arrival in the PICU (p<0.05)
Overall, patients from outlying EDs had a significantly shorter mean pre-PICU duration of IV terbutaline treatment than those from our ED; 0.69 h ± 1.38 h vs 2.91 h ± 2.47 h, respectively (p=0.000),
Similarly, there was a significant difference in requirement for mechanical ventilation between the two groups; 21 pts-60%- from outlying EDs and 14 pts -16%- from own ED (p=0.001).
Seventy-six patients (63%) did not require respiratory mechanical support; 21 patients (17%) required BiPAP and 23 patients (19%) required tracheal intubation and mechanical ventilation; the periods of pre-PICU terbutaline infusion for them were 2.61 h ± 2.47 h, 2.04 h ± 2.54 h and 0.97 h ± 1.59 h, respectively (p=0.015; figure 2).
None of the patients experienced any life-threatening adverse events due to IV terbutaline.
Conclusions
Early administration of continuous infusion of terbutaline in the ED may reduce the need for mechanical respiratory (invasive and non-invasive) support in severe pediatric asthma.
Patients who were transferred from outlying, non-tertiary care, hospitals’ ED(s) to our PICU, showed a higher incidence of progression to respiratory failure in association with shorter durations of pre-PICU intravenous terbutaline treatments.
Speculations
Outlying, non-tertiary care, hospitals’ ED(s) may not have experience with IV terbutaline, its potential side effects and the required patient monitoring; this may result in a delayed IV terbutaline administration and a higher incidence of acute respiratory failure.
Abstract
Introduction: Severe pediatric asthma, if not immediately and aggressively treated, may progress to acute respiratory failure requiring mechanical ventilation in the PICU.
Hypothesis: Timely initiation of IV terbutaline infusion in severe asthma reduces the incidence of acute respiratory failure.
Methods: A retrospective chart review of patients admitted to the PICU with severe asthma and received continuous intravenous infusion of terbutaline was conducted. The patients were divided into 2 categories; patients who were transported to our PICU from outlying emergency departments (ED) and patients who were transferred from our own ED to the PICU. We evaluated these patients’ responses to terbutaline and outcome.
Results: One hundred and twenty (120) patients were studied, 42 females and 78 males with a mean age of 6.8 y ± 4.2 y. One hundred eighteen (118) patients survived and 2 patients died (brain death) in the PICU from an earlier episode of cardiac arrest at home. Thirty-five (35) patients were transferred from outlying ED(s) and 85 patients from our ED. Seventy-six patients (76) had their terbutaline infusion started prior to their arrival in the PICU and 44 patients had it started after. Seventy-six patients (63%) did not require respiratory mechanical support and were breathing spontaneously throughout their course, 21 patients (17%) received BiPAP and 23 patients (19%) required tracheal intubation and mechanical ventilation. The periods of Pre-PICU terbutaline infusion were 2.61 h ± 2.47 h, 2.04 h ± 2.54 h and 0.97 h ± 1.59 h, respectively (p=0.015). Patients transported from outlying hospitals’ ED(s) had shorter mean durations of IV terbutaline than those transferred from our ED, measuring 0.69 h ± 1.38 h and 2.91 h ± 2.47 h, respectively (p=0.000).
Conclusions: Early administration of continuous infusion of terbutaline in the ED may reduce the need for mechanical respiratory (invasive and non-invasive) support in severe pediatric asthma. Patients who were transferred from outlying, non-tertiary care, hospitals’ ED(s) to our PICU, showed a higher incidence of progression to respiratory failure in association with shorter durations of pre-PICU intravenous terbutaline treatments.
Introduction
Preventing acute asthma patients from deteriorating to an acute respiratory failure status is crucial as it reduces morbidity, mortality rate and treatment costs within the PICU.
Our study focused on the efficacy of continuous IV administration of terbutaline, in the pre-PICU phase, in severe pediatric asthma.
Hypothesis:
We tested the hypothesis that early administration of intravenous terbutaline, well before admission to the PICU, is beneficial in preventing acute respiratory failure and its resulting need for invasive or non-invasive mechanical ventilation.
Materials and Methods
A retrospective chart review of patients admitted to the PICU over a period of 3 years (2007 – 2010) with severe asthma and who received continuous intravenous infusion of terbutaline, was conducted.
The patients were divided into 2 categories:
patients who were transported to our PICU from outlying, non-tertiary care hospitals’ emergency departments (ED)
patients who were transferred from our own ED to the PICU.
We evaluated these patients’ periods of pre-PICU IV terbutaline treatment, their responses to it and their outcome.
The study received IRB approval.
Statistical Analysis (MinitabR):
The patients’ demographics and vital signs (respiratory rate and heart rate) prior to initiation of terbutaline drips, in the 2 categories of patients, were compared by the unpaired t test.
The periods of pre-PICU terbutaline IV treatment for patients transported from outlying hospitals’ ED and from our own ED, were also compared by the unpaired t test.
Periods of pre-PICU IV terbutaline treatment for patients who did not require any mechanical respiratory support, patients who were successfully treated by non-invasive support (BiPAP) and those requiring invasive mechanical ventilation via a tracheal tubes, were compared by ANOVA.
Non-parametric data regarding the breakdown of the number of patients requiring or not requiring mechanical ventilation, in the 2 groups, were analyzed by the Chi Square test.
We rejected the null hypothesis at a p≤0.05.
Figure 1: Summary of results
Table 1: Patient data
 Pts from  n
Age (years)
Loading Dose (mcg/kg)
Max. Drip Dose (mcg/kg/min)
Resp Rate Prior to IV Terb
Heart Rate Prior to IV Terb
Pre-PICU Terb (hrs)
Mech. Vent.
(inv+non-inv)
Outlying EDs 35
8.43 ±4.89
4.2
±0.7
0.8
± 0.6
39.4
±14.1
139.9
±20.5
0.69
± 1.38
21/35
(60%)
The LIJ ED 85
6.26 ±3.94
4.4
±0.6
0.7
40.2
±13.4
143.8
± 23.7
2.91
± 2.47*
14/85
(16%)
 p value
NS (>0.05)
*0.000
0.001
Figure 2:
MV- Mechanical Ventilation, NIPPV – Noninvasive positive pressure ventilation (BiPAP); SV – spontaneous ventilation

19. #732
Early Administration of Intravenous Terbutaline in Severe Pediatric Asthma
May Reduce the Incidence of Acute Respiratory Failure
Sule Doymaz1, M.D., James Schneider1, M. D., Mayer Sagy2, M. D.
The Divisions of Pediatric Critical Care Medicine at 1Cohen Children’s Medical Center of New York, New Hyde Park, NY and 2New York University Medical Center, New York, NY.
Please place NHS/LIJ
logo/emblem here
Contact Information:
Results
Of the 120 patients studied, 118 survived and 2 died (brain death) in the PICU from an earlier episode of cardiac arrest at home.
Thirty-five (35) patients were transferred from outlying ED(s) and 85 patients from our ED; these two categories of patients were clinically and demographically similar (figure 1).
In 25 patients (71%) from outlying EDs, and in only 17 pts (20%) from our own ED terbutaline started after arrival in the PICU (p<0.05)
Overall, patients from outlying EDs had a significantly shorter mean pre-PICU duration of IV terbutaline treatment than those from our ED; 0.69 h ± 1.38 h vs 2.91 h ± 2.47 h, respectively (p=0.000),
Similarly, there was a significant difference in requirement for mechanical ventilation between the two groups; 21 pts-60%- from outlying EDs and 14 pts -16%- from own ED (p=0.001).
Seventy-six patients (63%) did not require respiratory mechanical support; 21 patients (17%) required BiPAP and 23 patients (19%) required tracheal intubation and mechanical ventilation; the periods of pre-PICU terbutaline infusion for them were 2.61 h ± 2.47 h, 2.04 h ± 2.54 h and 0.97 h ± 1.59 h, respectively (p=0.015; figure 2).
None of the patients experienced any life-threatening adverse events due to IV terbutaline.
Conclusions
Early administration of continuous infusion of terbutaline in the ED may reduce the need for mechanical respiratory (invasive and non-invasive) support in severe pediatric asthma.
Patients who were transferred from outlying, non-tertiary care, hospitals’ ED(s) to our PICU, showed a higher incidence of progression to respiratory failure in association with shorter durations of pre-PICU intravenous terbutaline treatments.
Speculations
Outlying, non-tertiary care, hospitals’ ED(s) may not have experience with IV terbutaline, its potential side effects and the required patient monitoring; this may result in a delayed IV terbutaline administration and a higher incidence of acute respiratory failure.
Abstract
Introduction: Severe pediatric asthma, if not immediately and aggressively treated, may progress to acute respiratory failure requiring mechanical ventilation in the PICU.
Hypothesis: Timely initiation of IV terbutaline infusion in severe asthma reduces the incidence of acute respiratory failure.
Methods: A retrospective chart review of patients admitted to the PICU with severe asthma and received continuous intravenous infusion of terbutaline was conducted. The patients were divided into 2 categories; patients who were transported to our PICU from outlying emergency departments (ED) and patients who were transferred from our own ED to the PICU. We evaluated these patients’ responses to terbutaline and outcome.
Results: One hundred and twenty (120) patients were studied, 42 females and 78 males with a mean age of 6.8 y ± 4.2 y. One hundred eighteen (118) patients survived and 2 patients died (brain death) in the PICU from an earlier episode of cardiac arrest at home. Thirty-five (35) patients were transferred from outlying ED(s) and 85 patients from our ED. Seventy-six patients (76) had their terbutaline infusion started prior to their arrival in the PICU and 44 patients had it started after. Seventy-six patients (63%) did not require respiratory mechanical support and were breathing spontaneously throughout their course, 21 patients (17%) received BiPAP and 23 patients (19%) required tracheal intubation and mechanical ventilation. The periods of Pre-PICU terbutaline infusion were 2.61 h ± 2.47 h, 2.04 h ± 2.54 h and 0.97 h ± 1.59 h, respectively (p=0.015). Patients transported from outlying hospitals’ ED(s) had shorter mean durations of IV terbutaline than those transferred from our ED, measuring 0.69 h ± 1.38 h and 2.91 h ± 2.47 h, respectively (p=0.000).
Conclusions: Early administration of continuous infusion of terbutaline in the ED may reduce the need for mechanical respiratory (invasive and non-invasive) support in severe pediatric asthma. Patients who were transferred from outlying, non-tertiary care, hospitals’ ED(s) to our PICU, showed a higher incidence of progression to respiratory failure in association with shorter durations of pre-PICU intravenous terbutaline treatments.
Introduction
Preventing acute asthma patients from deteriorating to an acute respiratory failure status is crucial as it reduces morbidity, mortality rate and treatment costs within the PICU.
Our study focused on the efficacy of continuous IV administration of terbutaline, in the pre-PICU phase, in severe pediatric asthma.
Hypothesis:
We tested the hypothesis that early administration of intravenous terbutaline, well before admission to the PICU, is beneficial in preventing acute respiratory failure and its resulting need for invasive or non-invasive mechanical ventilation.
Materials and Methods
A retrospective chart review of patients admitted to the PICU over a period of 3 years (2007 – 2010) with severe asthma and who received continuous intravenous infusion of terbutaline, was conducted.
The patients were divided into 2 categories:
patients who were transported to our PICU from outlying, non-tertiary care hospitals’ emergency departments (ED)
patients who were transferred from our own ED to the PICU.
We evaluated these patients’ periods of pre-PICU IV terbutaline treatment, their responses to it and their outcome.
The study received IRB approval.
Statistical Analysis (MinitabR):
The patients’ demographics and vital signs (respiratory rate and heart rate) prior to initiation of terbutaline drips, in the 2 categories of patients, were compared by the unpaired t test.
The periods of pre-PICU terbutaline IV treatment for patients transported from outlying hospitals’ ED and from our own ED, were also compared by the unpaired t test.
Periods of pre-PICU IV terbutaline treatment for patients who did not require any mechanical respiratory support, patients who were successfully treated by non-invasive support (BiPAP) and those requiring invasive mechanical ventilation via a tracheal tubes, were compared by ANOVA.
Non-parametric data regarding the breakdown of the number of patients requiring or not requiring mechanical ventilation, in the 2 groups, were analyzed by the Chi Square test.
We rejected the null hypothesis at a p≤0.05.
Figure 1: Summary of results
Table 1: Patient data
 Pts from  n
Age (years)
Loading Dose (mcg/kg)
Max. Drip Dose (mcg/kg/min)
Resp Rate Prior to IV Terb
Heart Rate Prior to IV Terb
Pre-PICU Terb (hrs)
Mech. Vent.
(inv+non-inv)
Outlying EDs 35
8.43 ±4.89
4.2
±0.7
0.8
± 0.6
39.4
±14.1
139.9
±20.5
0.69
± 1.38
21/35
(60%)
The LIJ ED 85
6.26 ±3.94
4.4
±0.6
0.7
40.2
±13.4
143.8
± 23.7
2.91
± 2.47*
14/85
(16%)
 p value
NS (>0.05)
*0.000
0.001
Figure 2:
MV- Mechanical Ventilation, NIPPV – Noninvasive positive pressure ventilation (BiPAP); SV – spontaneous ventilation

20. Ulcerative Colitis: From A to V
Toni Webster, Heather Appelbaum, Toba Weinstein, Nelson Rosen,
Jeremiah Levine
Steven and Alexandra Cohen Children’s Medical Center, Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York
Introduction
Findings
Discussion
Ulcerative colitis (UC) is a chronic inflammatory disease
UC is limited primarily to the colonic mucosa with continuous involvement
Etiology of UC is unknown
Evidence suggesting both genetic and environmental factors play a role in disease pathogenesis
Vaginoplasty using sigmoid colon is an accepted technique for creation of a neovagina
UC affecting the neovagina is a rare phenomenon reported in only four adult patients1,2,3,4 
Rectal bleeding and colonic inflammation can result from:
Acute or chronic infection
Intrinsic inflammatory bowel disease
Surgical diversion of segments of the colorectum
Few case reports of UC involving a neovagina: 
In 1991, first case of UC of a neovagina and rectum reported
Treated successfully with oral sulfasalazine2
In 1992, patient with ulcerative colitis requiring subtotal colectomy
Neovaginal pathology consistent with diversion colitis or UC3 
No treatment required for sigmoid neovagina 
In 2000, patient with UC of the neovagina and colon
Treated with topical therapy4 
In 2010, patient with UC of the colon and neovagina
Required total colectomy
Neovagina treated only with topical therapy1 a b c
Figure 1.  (a) Patient lying with left side down demonstrating kissing perineal ulcers  (b) Patient in supine position demonstrating prolapsed vaginoplasty  (c) Close view of ulcerated sigmoid neovagina and perineal ulcer a b c
History & Physical Examination
17 year old XY female with a history of gonadal dysgenesis with sigmoid graft vaginoplasty during infancy
Initial presentation:
Bloody, mucousy vaginal discharge
Abdominal pain
Bloody diarrhea
Weight loss
Findings on physical examination:
Perineal ulcers
Neovaginal prolapse with ulcerations
Diffuse abdominal pain
No peritoneal signs 
Treatment
Conclusion
Figure 2.  (a) Neovaginal biopsy: island of intact colonic mucosa with surrounding ulceration (b) Neovaginal biopsy: chronic active colitis (c) Colonic biopsy: colitis with erosions, granulation tissue and extensive crypt loss
First described pediatric case in which a patient developed UC in the colon with simultaneous involvement of the sigmoid neovagina
Only reprted case in which a patient was refractory to medical therapy, including biologics
Only reported case requiring total colectomy and vaginectomy
Special consideration must be given to the potential long term consequences of using a colonic conduit for vaginal replacement 
Recognition that ulcerative colitis can occur in patients with a colonic neovaginal graft is imperative when considering the risks and benefits of this technical approach to the creation of a neovagina
Treatment
Persistent neovaginal and colonic bleeding refractory to:
Intravenous and topical steroids
Methotrexate
Infliximab 
Surgical intervention:
Subtotal colectomy
Pathology demonstrated extensive mucosal ulceration and denudation with patchy hemorrhage consistent with fulminant pancolitis
Vaginectomy and excision of remaining rectal tissue
Pathologic findings similar to previously excised colonic specimen
Evaluation
Significant laboratory results:
Leukocytosis
Thrombocytopenia
Abdominal and pelvic CT:
Pancolitis
Colonoscopy:
Active colitis with diffuse ulcerations
Neovaginal biopsies with diffuse ulcerations
References
1. Lima M, Ruggeri G, Randi B, et al : Vaginal replacement in the pediatric age group: a 34-year experience of intestinal vaginoplasty in children and young girls. Journal of Pediatric Surgery 2010; 45:
2. Froese DP, Haggit RC, Friend WG: Ulcerative colitis in the autotransplanted neovagina. Gastroenterology 1991; 100:
3. Hennigan TW, Theodorou NA: Ulcerative colitis and bleeding from a colonic vaginoplasty. Journal of the Royal Society of Medicine 1992; 85:
4. Malka D, Anquetil C, Ruszniewski P: Ulcerative colitis in a sigmoid neovagina. The New England Journal of Medicine 2000; 343:369.